All In Biotech

Drug Trial Radar · NCT02175225

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Study of Deferoxamine Mesylate in Intracerebral Hemorrhage

Last checked: Nov 19, 2026Latest source record: May 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 294 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

294

Actual

Start

Oct 2014

Primary completion

Feb 10, 2018

Study completion May 30, 2018

Sponsor

Lead sponsor
Beth Israel Deaconess Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS); Massachusetts General Hospital; University of Massachusetts, Worcester; University of Pennsylvania; Johns Hopkins University; Duke University; University of North Carolina; University of Florida; Henry Ford Hospital; Ohio State University; St. Joseph's Hospital and Medical Center, Phoenix; University of California, San Francisco; Oregon Health and Science University; Yale New Haven Health System Center for Healthcare Solutions; University of Iowa; Hartford Hospital; The University of Texas Health Science Center, Houston; Rhode Island Hospital; Stanford University; University of Washington; University of Calgary; Hopital de l'Enfant-Jesus; University of Alberta; Rush University Medical Center; University Hospitals Cleveland Medical Center; Columbia University; Weill Medical College of Cornell University; NYU Langone Health; Mount Sinai Hospital, New York; Loyola University
First posted
Jun 26, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage. The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.

Conditions

  • Intracerebral Hemorrhage

Interventions

  • Deferoxamine MesylateDrug

  • Placebo (for Deferoxamine Mesylate)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 DaysTime frame: 90 days
  2. Number of Subjects Experiencing Serious Adverse EventsTime frame: 90 days
  3. Number of Subjects With Serious Adverse Events Within 7 DaysTime frame: 7 days

Locations

28 sites in 2 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital / Barrow Neurological Institute

    Phoenix, Arizona

  • Stanford University Medical Center

    Palo Alto, California

  • San Francisco General Hospital

    San Francisco, California

  • Yale New Haven Hospital

    New Haven, Connecticut

  • University of Florida

    Jacksonville, Florida

  • Loyola University Medical Center

    Chicago, Illinois

  • RUSH University Medical Center

    Chicago, Illinois

  • University of Iowa Medical Center

    Iowa City, Iowa

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Columbia University

    New York, New York

  • Mount Sinai Hospital

    New York, New York

  • NYU Langone Medical Center

    New York, New York

  • Weill Medical College of Cornell University

    New York, New York

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • University Hospital Case Medical Center

    Cleveland, Ohio

  • The Ohio State University Medical Center

    Columbus, Ohio

  • Oregon Health & Science University Medical Center

    Portland, Oregon

  • University of Pennsylvania Medical Center

    Philadelphia, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of Texas Health Sciences Center

    Houston, Texas

  • CHU de Québec - Hôpital de l'Enfant-Jésus

    Québec, Canada

  • Foothills Hospital - University of Calgary

    Calgary, Alberta, Canada

  • University of Alberta - Mackenzie Health Sciences Centre

    Edmonton, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.